Skip to main content
Breadcrumb
Home
Publications
Publications
Johannes C, Layton JB , Beachler DM, Ziemiecki RM , Li L, Danysh HE , Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A . Risk of acute kidney injury in real-world use of dapagliflozin . Presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.
Johannes C, Layton JB , Beachler DC, Ziemiecki RM , Li L, Danysh HE , Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A . Risk of severe complications of urinary tract infection in real-world use of dapagliflozin . Poster presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.
Forns J , Dudukina E, Hagg D, Szentkuti EP, Gembert K, Plana E , Gilsenan A , Horvath-Puho E, Reutfors J, Rebordosa C . Cohort study of the incidence of major cardiovascular events in new adult users of lisdexamfetamine and remote adult users of other attention-deficit/hyperactivity disorder treatments . Poster presented at the 2021 8th World Congress on ADHD Virtual Event; May 6, 2021.
Arana A , Margulis AV , Varas-Lorenzo C, Bui CL , Gilsenan A , McQuay LJ, Reynolds M , Rebordosa C , Franks B, de Vogel S, Appenteng K, Perez-Gutthann S . Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom . Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):237-47. doi: 10.1002/pds.5150
Hollis K , Gilsenan A . Design and implementation of surveys to assess patient and health care provider understanding of risks and safe use conditions. In: Andrews EB, Moore M, editors. Mann's pharmacovigilance . 3rd ed. Hoboken: NJ. John Wiley & Sons; 2014.